Search

Your search keyword '"American Academy of Neurology"' showing total 3,478 results
Start Over Descriptor "American Academy of Neurology"
3,478 results on '"American Academy of Neurology"'

52. NeuroSense Announces First Quarter 2024 Business Update

Subjects
Company earnings/profit, General interest, News, opinion and commentary, American Academy of Neurology
Abstract

CAMBRIDGE: NeuroSense has issued the following news release: NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ('NeuroSense'), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update. Corporate Highlights [...]

Published
2024

53. Development of a core outcome set for quality of life for adults with drug‐resistant epilepsy: A multistakeholder Delphi consensus study.

Author

Chiang, Sharon, Moss, Robert, Stern, John M., Hughes, Inna, Josephson, S. Andrew, Pearce, Jennifer R., Kopald, Brandon E., Patel, Anup D., and Rao, Vikram R.

Subjects
*EPILEPSY, *PSYCHOGENIC nonepileptic seizures, *DELPHI method, *QUALITY of life, *ADULTS, *WORK measurement
Abstract

Objective: In 2017, the American Academy of Neurology (AAN) convened the AAN Quality Measurement Set working group to define the improvement and maintenance of quality of life (QOL) as a key outcome measure in epilepsy clinical practice. A core outcome set (COS), defined as an accepted, standardized set of outcomes that should be minimally measured and reported in an area of health care research and practice, has not previously been defined for QOL in adult epilepsy. Methods: A cross‐sectional Delphi consensus study was employed to attain consensus from patients and caregivers on the QOL outcomes that should be minimally measured and reported in epilepsy clinical practice. Candidate items were compiled from QOL scales recommended by the AAN 2017 Quality Measurement Set. Inclusion criteria to participate in the Delphi study were adults with drug‐resistant epilepsy diagnosed by a physician, no prior diagnosis of psychogenic nonepileptic seizures or a cognitive and/or developmental disability, or caregivers of patients meeting these criteria. Results: A total of 109 people satisfied inclusion/exclusion criteria and took part in Delphi Round 1 (patients, n = 95, 87.2%; caregivers, n = 14, 12.8%), and 55 people from Round 1 completed Round 2 (patients, n = 43, 78.2%; caregivers, n = 12, 21.8%). One hundred three people took part in the final consensus round. Consensus was attained by patients/caregivers on a set of 36 outcomes that should minimally be included in the QOL COS. Of these, 32 of the 36 outcomes (88.8%) pertained to areas outside of seizure frequency and severity. Significance: Using patient‐centered Delphi methodology, this study defines the first COS for QOL measurement in clinical practice for adults with drug‐resistant epilepsy. This set highlights the diversity of factors beyond seizure frequency and severity that impact QOL in epilepsy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

54. Long-term prognosis and mortality in patients with progressive multifocal leukoencephalopathy.

Author

Jinnam Kim, Changhyup Kim, Jung Ah Lee, Se Ju Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, and Young Goo Song

Subjects
*PROGRESSIVE multifocal leukoencephalopathy, *JOHN Cunningham virus, *HIGHLY active antiretroviral therapy, *SURVIVAL rate, *HIV-positive persons
Abstract

배경: This study aimed to investigate the prognosis and prognostic factors for mortality in progressive multifocal leukoencephalopathy (PML) patients through a long observation period. 방법: This retrospective study was conducted in two tertiary hospitals in South Korea from 1999 to 2021. Patients diagnosed with PML were reviewed according to the American Academy of Neurology diagnostic criteria. The primary endpoint was long-term overall mortality. Each patient was followed up till death or the end of the study period. 결과: Total of 47 PML patients were included. Of 27 patients (57.4%) were diagnosed with HIV. Median last follow-up modified Rankin Scale (mRS) score was higher in the non-HIV PML group than that in the HIV group (5 vs. 4, p=0.020). Median survival duration was lower in the non-HIV group (184 vs. 1,564 days). The 1-year and overall mortality rates of PML patients were significantly higher in the non-HIV group than that in HIV group (60.0% vs. 25.9%, p=0.019; 80.0% vs. 40.7%, p=0.007). Initial mRS score (HR 1.685, p=0.038) and highly active antiretroviral therapy (HAART) in HIV patients (HR 0.374, p=0.013) had a significant effect on overall mortality. 결론: Survival duration of HIV-positive PML patients receiving HAART improved; however, the mortality rate is still high. Introduction of HAART in HIV patients and initial mRS score are significant prognostic factors for overall mortality in PML patients. [ABSTRACT FROM AUTHOR]

Published
2022

55. Quality of life during usual epilepsy care for anxiety or depression symptoms: Secondary patient-reported outcomes in a randomized trial of remote assessment methods.

Author

Munger Clary, Heidi M., Snively, Beverly M., Kumi-Ansu, Yaw, Alexander, Halley B., Kimball, James, Duncan, Pamela, Conner, Kelly, Christopher, Jerryl, Lohana, Paneeni, and Brenes, Gretchen A.

Subjects
*MENTAL depression, *MENTAL illness, *QUALITY of life, *ANXIETY, *PATIENT portals
Abstract

Anxiety and depression are highly prevalent and impactful in epilepsy. American Academy of Neurology quality measures emphasize anxiety and depression screening and quality of life (QOL) measurement, yet usual epilepsy care QOL and anxiety/depression outcomes are poorly characterized. The main objective was to assess 6-month QOL, anxiety and depression during routine care among adults with epilepsy and baseline anxiety or depression symptoms; these were prespecified secondary outcomes within a pragmatic randomized trial of remote assessment methods. Adults with anxiety or depression symptoms and no suicidal ideation were recruited from a tertiary epilepsy clinic via an electronic health record (EHR)-embedded process. Participants were randomized 1:1 to 6 month outcome collection via patient portal EHR questionnaires vs. telephone interview. This report focuses on an a priori secondary outcomes of the overall trial, focused on patient-reported health outcomes in the full sample. Quality of life, (primary health outcome), anxiety, and depression measures were collected at 3 and 6 months (Quality of Life in Epilepsy-10, QOLIE-10, Generalized Anxiety Disorder-7, Neurological Disorders Depression Inventory-Epilepsy). Change values and 95 % confidence intervals were calculated. In post-hoc exploratory analyses, patient-reported anxiety/depression management plans at baseline clinic visit and healthcare utilization were compared with EHR-documentation, and agreement was calculated using the kappa statistic. Overall, 30 participants (15 per group) were recruited and analyzed, of mean age 42.5 years, with 60 % women. Mean 6-month change in QOLIE-10 overall was 2.0(95 % CI −6.8, 10.9), and there were no significant differences in outcomes between the EHR and telephone groups. Mean anxiety and depression scores were stable across follow-up (all 95 % CI included zero). Outcomes were similar regardless of whether an anxiety or depression action plan was documented. During the baseline interview, most participants with clinic visit EHR documentation indicating action to address anxiety and/or depression reported not being offered a treatment(7 of 12 with action plan, 58 %), and there was poor agreement between patient report and EHR documentation (kappa=0.22). Healthcare utilization was high: 40 % had at least one hospitalization or emergency/urgent care visit reported and/or identified via EHR, but a third (4/12) failed to self-report an EHR-identified hospitalization/urgent visit. Over 6 months of usual care among adults with epilepsy and anxiety or depression symptoms, there was no significant average improvement in quality of life or anxiety/depression, suggesting a need for interventions to enhance routine neurology care and achieve quality of life improvement for this group. • Outcomes in usual care were assessed among adults with anxiety and/or depression. • Only 40 % of epilepsy clinic visits documented action for baseline mental health symptoms. • Quality of life did not improve significantly over 6 months routine neurology care. • Agreement was poor between patient-report & health record documented treatment plan. • Major healthcare utilization was common (40 %), yet under-reported by participants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

56. New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines—Highlights From the 2023 American Academy of Neurology Conference.

Author

Marcus, Revital

Subjects
*POST-acute COVID-19 syndrome, *CENTRAL nervous system, *INTRANASAL medication, *ALZHEIMER'S disease, *MIGRAINE
Abstract

This Medical News article discusses research presented at the recent American Academy of Neurology Conference. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

57. Acute Treatment of Headache (Focus on Migraine).

Author

Chiang, Chia-Chun and Halker Singh, Rashmi B.

Subjects
*HEADACHE, *MIGRAINE, *CLUSTER headache, *EUROPEAN integration, *CALCITONIN gene-related peptide
Abstract

Acute treatments for migraine and cluster headache are necessary to abort attacks, relieve pain and associated symptoms, and restore an individual's ability to function. Acute headache treatments consist of a variety of medication and nonmedication options. In this article, we discuss the approach to acute treatment of migraine and cluster headache. We summarize the level of evidence to support each acute medication class according to recent systematic reviews and meta-analyses, as well as guideline recommendations from the American Headache Society, American Academy of Neurology, and European Federation of Neurological Society. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

58. Antiseizure Medication Withdrawal in Seizure-Free Patients: What is New for the Pediatrician?

Author

Gupta, Arpita and Kumar, Kunal

Subjects
PEDIATRICIANS, STATUS epilepticus, AGE, DRUGS, AGE groups
Abstract

The American Academy of Neurology (AAN) has recently updated its practise advisory on antiseizure medication withdrawal. The recommendations have been formulated for pediatric as well as adult epilepsy, with emphasis on the risk factors for seizure relapse, occurrence of status epilepticus or death on drug withdrawal, and effect on quality of life in both age groups. We herein list the important aspects of the updated recommendations in pediatric epilepsy for the benefit of the general pediatricians. The full update is available at the AAN website. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

59. Researchers to receive first-ever Ralph L. Sacco Scholarships for Brain Health

Subjects
Societies, Mental health, Scholarships, Associations, institutions, etc., Health, Psychology and mental health, American Academy of Neurology
Abstract

2024 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- MINNEAPOLIS and DALLAS - The American Academy of Neurology and the American Heart [...]

Published
2024

60. Can inflammation in early adulthood affect memory, thinking in middle age?

Subjects
Dementia, Inflammation, Mental health, C-reactive protein, Health, Psychology and mental health, American Academy of Neurology
Abstract

2024 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- MINNEAPOLIS - Having higher levels of inflammation in your 20s and 30s may [...]

Published
2024

61. Rush University Medical Center Researcher Illuminates Research in Brain Death (Role of Clinical and Multimodality Neuroimaging in the Evaluation of Brain Death/Death by Neurologic Criteria and Recent Highlights from 2023 Updated Guidelines)

Subjects
Brain, Brain research, Brain death, Health care industry, Diagnostic imaging, Health care industry, Health, American Academy of Neurology, Rush University. Medical Center
Abstract

2024 JUL 12 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on brain death have been presented. According to news originating from [...]

Published
2024

62. Guideline issued for people with epilepsy who may become pregnant

Subjects
Mental health, Anticonvulsants, Pregnant women, Epilepsy, Autism, Health, Psychology and mental health, American Academy of Neurology
Abstract

2024 MAY 27 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MINNEAPOLIS - A new guideline [...]

Published
2024

63. CHPA RESPONSE TO STUDY EXAMINING PRESCRIPTION ACID REFLUX DRUGS FOLLOWING INACCURATE MEDIA REPORTS:

Subjects
Nonprescription drugs, Gastrointestinal agents, Gastroesophageal reflux -- Drug therapy, News, opinion and commentary, American Academy of Neurology
Abstract

WASHINGTON, DC -- The following information was released by the Consumer Healthcare Products Association (CHPA): 'This study only evaluated the prescription use of proton pump inhibitors (PPIs), H2 receptor antagonists [...]

Published
2024

64. Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today(r)

Subjects
Drugs -- Vehicles, Multiple sclerosis -- Research, Drug delivery systems -- Research, General interest, News, opinion and commentary, American Academy of Neurology
Abstract

NEW YORK: Tiziana Life Sciences Ltd. has issued the following news release: Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough immunomodulation therapies via [...]

Published
2024

66. Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Subjects
Drugs -- Vehicles, Multiple sclerosis, Drug delivery systems, Business, international, American Academy of Neurology
Abstract

(GlobeNewswire) - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a study [...]

Published
2024

67. Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today(R)

Subjects
Drugs -- Vehicles, Multiple sclerosis -- Development and progression, Drug delivery systems, Business, international, American Academy of Neurology
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in [...]

Published
2024

70. TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Subjects
American Academy of Neurology, Briumvi (Medication)
Abstract

ENPNewswire-April 19, 2024--TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 18042024 [...]

Published
2024

71. France : New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Subjects
Sanofi S.A. -- Product development, Multiple sclerosis, Pharmaceutical industry -- Product development, Business, international, American Academy of Neurology
Abstract

Sanofis CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at [...]

Published
2024

72. 8-K: Clene Inc

Subjects
Cybernet Data Systems Inc., Computer services industry, Computer services industry, Business, general, American Academy of Neurology
Abstract

(EDGAR Online via COMTEX) -- false 0001822791 0001822791 2024-04-16 2024-04-16 0001822791 clnn:CommonStock00001ParValueCustomMember 2024-04-16 2024-04-16 0001822791 clnn:WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember 2024-04-16 2024-04-16 -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------------------------------------------------------------------- [...]

Published
2024

73. Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Subjects
Sanofi S.A. -- Product development, Multiple sclerosis, Pharmaceutical industry -- Product development, Business, international, American Academy of Neurology
Abstract

Paris: Sanofi has issued the following press release: Sanofi's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple [...]

Published
2024

74. Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Subjects
Brain damage -- Care and treatment, Multiple sclerosis -- Care and treatment, Diseases -- Relapse, Business, international, American Academy of Neurology, Ocrevus (Medication)
Abstract

Basel: Hoffmann-La Roche has issued the following press release: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS(r) (ocrelizumab), an [...]

Published
2024

75. Novartis Kesimpta six-year efficacy data show substantial benefits in recently diagnosed treatment-naE¯ve people with relapsing multiple sclerosis

Subjects
Novartis Pharmaceuticals Corp., Multiple sclerosis -- Development and progression -- Care and treatment, Ofatumumab, Pharmaceutical industry, Diagnostic imaging, Business, News, opinion and commentary, American Academy of Neurology
Abstract

Continuous Kesimpta treatment for up to six years showed sustained efficacy in recently diagnosed ([less than or equal to]3 years) treatment-naȯve people living with relapsing multiple sclerosis (RMS) in an [...]

Published
2024

76. Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Biological products industry, Diseases -- Relapse, Biotechnology industry, B cells, Drug approval, Business, Business, international, American Academy of Neurology, Ocrevus (Medication)
Abstract

- Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through [...]

Published
2024

77. Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naive people with relapsing multiple sclerosis

Subjects
Novartis Pharmaceuticals Corp., Multiple sclerosis -- Development and progression -- Care and treatment, Ofatumumab, Pharmaceutical industry, Diagnostic imaging, Business, international, American Academy of Neurology
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Continuous Kesimpta(R) treatment for up to six years showed sustained efficacy in recently diagnosed (less-than or equal to3 years) treatment-naive people living with relapsing [...]

Published
2024

78. argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Subjects
United States. Food and Drug Administration, Banking, finance and accounting industries, Business, American Academy of Neurology, Vyvgart (Medication), Vyvgart Hytrulo (Medication)
Abstract

ADHERE data show VYVGART (R) Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over [...]

Published
2024

81. argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Subjects
American Academy of Neurology, Vyvgart (Medication), Vyvgart Hytrulo (Medication)
Abstract

ENPNewswire-April 16, 2024--argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 16042024 - Amsterdam, the [...]

Published
2024

82. EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY(r) (AAN) ANNUAL MEETING

Subjects
Eisai Inc., Advertising executives -- Research, Alzheimer's disease -- Research, Pharmaceutical industry -- Research, General interest, News, opinion and commentary, American Academy of Neurology, Leqembi (Medication) -- Research
Abstract

NUTLEY: Eisai Inc. has issued the following news release: Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity [...]

Published
2024

83. Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology 2024

Subjects
American Academy of Neurology
Abstract

ENPNewswire-April 15, 2024--Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk [...]

Published
2024

88. Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Subjects
United States. Food and Drug Administration, American Academy of Neurology
Abstract

ENPNewswire-April 15, 2024--Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 12042024 [...]

Published
2024

91. NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Subjects
Medical research, Medicine, Experimental, Business, News, opinion and commentary, American Academy of Neurology
Abstract

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual [...]

Published
2024

92. Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Subjects
Immunoglobulin G, Business, News, opinion and commentary, American Academy of Neurology
Abstract

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE(TM)) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest [...]

Published
2024

93. Aquestive Therapeutics to Present Crossover Study Data for Libervant(TM) (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Subjects
United States. Food and Drug Administration, Diazepam, Epilepsy, Banking, finance and accounting industries, Business, American Academy of Neurology
Abstract

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the 'Company' or 'Aquestive'), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through [...]

Published
2024

94. EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

Subjects
Eisai Inc., Insomnia -- Research -- Development and progression, Viral antibodies -- Research, Advertising executives -- Research, Alzheimer's disease -- Development and progression -- Research, Antibodies -- Research, Pharmaceutical industry -- Research, Business, News, opinion and commentary, American Academy of Neurology, Leqembi (Medication) -- Research, Dayvigo (Medication) -- Research
Abstract

NUTLEY, N.J., April 12, 2024 /PRNewswire/ -- Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial [...]

Published
2024

95. AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA) for Preventive Treatment of Migraine

Subjects
Medicine, Preventive, Migraine -- Drug therapy, Preventive health services, Business, News, opinion and commentary, American Academy of Neurology, Qulipta (Medication)
Abstract

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine- Seventy percent of subjects achieved[greater [...]

Published
2024

96. Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024

Subjects
Autoimmunity, Autoantibodies, B cells, Machine learning, Enzymes -- Product development, Immunoglobulin G, Business, Business, international, American Academy of Neurology
Abstract

Company's lead pipeline program in IgG sculpting enzymes demonstrates rapid and sustained reduction of IgG levels and ability to address multiple pathogenic mechanisms Preclinical findings support S-1117's differentiated product profile [...]

Published
2024

99. Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI at 76th Annual Meeting of the American Academy of Neurology

Subjects
H. Lundbeck A/S, Pharmaceutical industry, American Academy of Neurology
Abstract

ENPNewswire-April 10, 2024--Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI at 76th Annual Meeting of the American Academy of Neurology (C)2024 ENPublishing - http://www.enpublishing.co.uk Release [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results